Lanthio Pharma signs deal for drug-discovery platform

Lanthio Pharma has signed a technology alliance deal with MorphoSys to jointly develop the LanthioPep drug-discovery platform technology.

No financial details of the deal have been disclosed.

LanthioPep can be used to identify lantipeptides, a novel class of peptides with improved ‘drug-like’ properties.

Lanthio Pharma has also raised €4.8m (£3.8m) in the first close of a Series A investment round by a syndicate led by BioGeneration Ventures and INKEF Capital that also included MorphoSys and Hanzepoort as investors.